Search alternatives:
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
Showing 21 - 40 results of 20,520 for search '(( significant case based ) OR ( significant ((largest decrease) OR (larger decrease)) ))', query time: 0.55s Refine Results
  1. 21
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 22
    Decrease of admissions and lead diagnoses.

    Decrease of admissions and lead diagnoses. by Petr Fulin (8380320)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 23
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 24
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 25
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 26
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 27
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 28
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 29
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 30
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 31
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 32
    Sensitivity analyses of seroprevalence with the largest sample size study omitted.

    Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)

    Published 2024
    Save to List
    Saved in:
  13. 33
    Significant genes identified in the gene-based test with GWAS summary data.

    Significant genes identified in the gene-based test with GWAS summary data. by Samantha Gonzales (8798435)

    Published 2025
    Save to List
    Saved in:
  14. 34
    Fig 1 -

    Fig 1 - by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 35
    Total and resource-specific absolute costs (in 2020 CAD) per quarter in 2020 and percentage change from 2018 and 2019 for all individuals in Ontario.

    Total and resource-specific absolute costs (in 2020 CAD) per quarter in 2020 and percentage change from 2018 and 2019 for all individuals in Ontario. by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 36
    Characteristics of the individuals in the first week of 2020 in Ontario and British Columbia.

    Characteristics of the individuals in the first week of 2020 in Ontario and British Columbia. by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 37
    Fig 2 -

    Fig 2 - by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 38
    Total and resource-specific absolute costs per quarter in 2020 (in 2020 CAD) and percentage change from 2018 and 2019 for all individuals in British Columbia.

    Total and resource-specific absolute costs per quarter in 2020 (in 2020 CAD) and percentage change from 2018 and 2019 for all individuals in British Columbia. by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 39
    Total healthcare costs per 10,000 person-weeks (in 2020 CAD) in each ISO week from January 1, 2018 to December 27, 2020 in Ontario and British Columbia (BC).

    Total healthcare costs per 10,000 person-weeks (in 2020 CAD) in each ISO week from January 1, 2018 to December 27, 2020 in Ontario and British Columbia (BC). by Seraphine Zeitouny (16954499)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 40
    Significant relationships between QOL measures on infusion day and day 7.

    Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: